Integrating Buprenorphine Into the SFGH AIDS Program

PHASE4CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
HIVBuprenorphineOpioid Dependence
Interventions
OTHER

Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting

Eligible opioid-dependent HIV-infected patients are randomly assigned to receive buprenorphine opioid agonist treatment for 12 months either in an integrated HIV primary care setting (intervention group) versus a non-integrated substance use treatment clinic setting (comparison group).

Trial Locations (1)

94110

UCSF Positive Health Program, San Francisco

All Listed Sponsors
collaborator

San Francisco Department of Public Health

OTHER_GOV

collaborator

The New York Academy of Medicine

OTHER

collaborator

Health Resources and Services Administration (HRSA)

FED

lead

University of California, San Francisco

OTHER

NCT00263458 - Integrating Buprenorphine Into the SFGH AIDS Program | Biotech Hunter | Biotech Hunter